Analyst stock forecast
Inhibikase Therapeutics, Inc. Forecast: $6.00 Analyst Target
IKT has a $6.00 target, Strong Buy rating and 9 analysts. As of 2026-08-16.
Direct answer
Inhibikase Therapeutics, Inc.'s average price target is $6.00.
The target implies +149% from the recorded current price, and the consensus rating is Strong Buy.
The low target implies +24.5%, the high target implies +232%, and the range spans 207.5% of the current price.
Forecast evidence checked August 16, 2026.
Get free Inhibikase Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.41
- Average price target
- $6.00
- High price target
- $8.00
- Low price target
- $3.00
- Low target gap
- +24.5%
- Target upside
- +149%
- High target gap
- +232%
- Target range width
- 207.5%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 16, 2026
- Valid through
- August 23, 2026
Explore related company data
Read the frequently asked questions.
What is Inhibikase Therapeutics, Inc.'s average price target?
Inhibikase Therapeutics, Inc.'s verified average price target is $6.00. The target range is $3.00 to $8.00.
How far are Inhibikase Therapeutics, Inc.'s low and high targets from the recorded price?
The low target implies +24.5%, while the high target implies +232%.
How many analysts are included in Inhibikase Therapeutics, Inc.'s consensus?
The verified consensus includes 9 analysts.
How is Inhibikase Therapeutics, Inc.'s target upside or downside calculated?
The average target of $6.00 is divided by the recorded price of $2.41, then one is subtracted to produce +149%. This does not guarantee a future return.
When was Inhibikase Therapeutics, Inc.'s analyst forecast verified?
The data was verified on 2026-08-16. The dataset is valid through 2026-08-23.